Drugs / Senl_1904A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03840317 | Jan 2019 → Sep 2021 | acute lymphoblastic leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Senl_1904A | “Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia” NCT03840317 ↗ |
| Modality | Cell therapy | “two different chimeric antigen receptor T cell immunotherapies (Senl\_1904A and Senl\_1904B)” NCT03840317 ↗ |